secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001654954-25-003611
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences Q4 net loss $4.2M, cash burn cut, pivots to GLP-1 metabolic health
--------------------------------------------------------------------------------

- Q4 2024 net loss $4.2M ($1.5M in Q4 2023) includes $2.3M non-cash inventory charge; full-year net loss $11.5M.
- Cash used in operations Q4 2024 $1.5M, down 32% YoY; expects ~$0.35M/month burn in Q2/Q3 2025.
- Cash and equivalents $3.2M at Dec 31, 2024; prior to pivot, runway limited given burn rate.
- New strategic direction: TAEUS as biomarker for monitoring GLP-1 drug patients, targeting pharma, concierge, primary care.
- Planned De Novo pivotal trial: multi-center, ~250 subjects, hypothesis-driven, with FDA pre-submission alignment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495425003611/0001654954-25-003611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495425003611/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-003611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer